Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists

Bioorg Med Chem Lett. 2008 Sep 15;18(18):5111-4. doi: 10.1016/j.bmcl.2008.07.129. Epub 2008 Aug 7.

Abstract

Vesicular monoamine transporter type 2 (VMAT2) is a newly emerging target for both diagnostic and therapeutic applications in diabetes mellitus. In pursuit of novel VMAT2 antagonists, we identified a potent hypoglycemic agent with a novel dihydropyridone scaffold. Several analogs were designed and synthesized. A preliminary structure activity relationship (SAR) showed that the dihydropyridone scaffold is required for the activity.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alkylation
  • Animals
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / drug therapy*
  • Hypoglycemic Agents / chemical synthesis*
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / pharmacology*
  • Male
  • Molecular Structure
  • Pyridones / chemical synthesis*
  • Pyridones / chemistry
  • Pyridones / pharmacology*
  • Rats
  • Rats, Inbred Lew
  • Structure-Activity Relationship
  • Tetrabenazine / analogs & derivatives*
  • Tetrabenazine / pharmacology
  • Vesicular Monoamine Transport Proteins / antagonists & inhibitors*

Substances

  • Hypoglycemic Agents
  • Pyridones
  • Vesicular Monoamine Transport Proteins
  • dihydrotetrabenazine
  • Tetrabenazine